FOURTH AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • June 1st, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
This Fourth Amendment (“Fourth Amendment”) to Exclusive License Agreement effective as of May 16, 2023 (“Fourth Amendment Effective Date”) is by and between: Eisai Inc., with its principal office at 200 Metro Blvd., Nutley, NJ 07110, United States of America (“Eisai”) and Allarity Therapeutics, Inc., with its principal office at 24 School Street, 2nd Floor, Boston MA 02108, together with its wholly-owned subsidiaries (“Allarity”) (formerly Oncology Venture A/S), with reference to the following:
AMENDMENT TO MODIFICATION AND EXCHANGE AGREEMENTModification and Exchange Agreement • June 1st, 2023 • Allarity Therapeutics, Inc. • Pharmaceutical preparations
THIS AMENDMENT TO MODIFICATION AND EXCHANGE AGREEMENT (the “Amendment”) dated as of May 26, 2023, is effective as of April 20, 2023, by and between Allarity Therapeutics, Inc., a Delaware corporation (the “Company”), and 3i, LP, a Delaware limited partnership (“Preferred Holder”). The Company and the Preferred Holder, each referred to herein as a “Party” and collectively, as the “Parties.”
